As coronavirus disease 2019 (COVID-19) has caused unprecedented morbidity and mortality in the global pandemic, effective strategies to treat and prevent the disease are urgently needed. Microvascular and macrovascular thromboembolism complications, including arterial thromboembolism, especially venous thromboembolism (VTE), appear to be common clinical manifestations of COVID-19 [1]. Prophylactic use of parenteral anticoagulants during hospitalization is recommended [2]. However, the risk of out-hospital thromboembolism remains, with multiple studies showing that the incidence of symptomatic venous thromboembolism is up to 2.5% [3].
